GSK vs INCY Stock Comparison
INCY currently leads GSK in this stock comparison, with AIQ scores of 68 vs 62. The clearest difference is risk resilience, while GSK has the stronger value profile.
What is the main difference between GSK and INCY?
INCY leads the current stock comparison as Incyte Corporation, with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
GSK plc vs Incyte Corporation
INCY leads
INCY leads by 6 AIQ points, primarily on Risk Resilience and Quality. Wall Street currently favors GSK on target upside.
Competitive: 4 of 6 evidence groups support INCY, and its signal state is cleanly positive.
GSK plc
Incyte Corporation
The Algovestiq AIQ Score currently favors INCY over GSK, 68 versus 62 as of Oct 31, 2026. INCY's advantage is driven primarily by stronger risk resilience and quality, while GSK holds the stronger value profile. INCY also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors GSK. 4 of 6 covered evidence groups favor INCY today, and the comparison is rated Competitive on stability. INCY lead: Stable — the AIQ differential has held near 6 points over 30 sessions.
Compare GSK plc and Incyte Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare GSK and INCY against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience46 vs 71INCY +25
- Quality73 vs 90INCY +17
- Value67 vs 52GSK +15
- Momentum51 vs 57INCY +6
4 of 6 evidence groups favor INCY. INCY’s edge is concentrated in risk resilience and quality; GSK keeps a meaningful value edge.
What changed since the last close
Latest scored session 2026-10-28, compared against the prior scored session 2026-10-27.
Largest factor move: Momentum -22
New signals
- Downtrend Structure Active — bearish, trend, long horizon
Largest factor move: Momentum +2
No signal started or stopped since the prior session; its 2 active signals are unchanged.
The lead changed hands: INCY moved ahead of GSK in the latest session.
Deeper signal detail for each name lives on its own signals page — GSK and INCY both carry a full feed there.
The central trade-off
INCY (Incyte Corporation): the stronger current systematic profile, led by risk resilience and quality.
GSK (GSK plc): the counter-case, on value, valuation, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
INCYINCY on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
INCYINCY on combined revenue and EPS growth.
Value
GSKGSK on the peer-relative Value factor, by 15 points.
Momentum
INCYINCY on the Momentum factor, by 6 points.
Lower downside
INCYINCY on Risk Resilience, by 25 points.
Analyst upside
GSKGSK on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors INCY, analyst targets favor GSK. That disagreement is the most useful thing on this page.
| Measure | GSK | INCY | Note |
|---|---|---|---|
| Implied upside to target | +21.2% | +4.5% | GSK has more room |
| Target dispersion | 0% | +50.1% | Lower is tighter analyst agreement |
| Consensus | Hold | Hold | Context, not a primary driver |
| Analysts covering | 1 | 15 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor INCY. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | INCY | 62 vs 68 |
| Fundamentals | INCY | revenue growth 10.2% vs 31.5%; EPS growth -74.4% vs 92.1%; TTM ROE 28.3% vs 29.7%; gross margin 73.3% vs 92.6%; operating margin 24.1% vs 31.6% |
| Valuation | GSK | Value 67 vs 52 |
| Technicals | INCY | Price vs 50-day -0.1% vs -0.4%; vs 200-day -6.9% vs 8.3% |
| Risk Resilience | INCY | Risk Resilience 46 vs 71 |
| Analyst expectations | GSK | Target upside 21.2% vs 4.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of GSK and INCY and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is moderate at 6 points.
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on INCY.
How the comparison changed
120 daily snapshots · Jun 29 – Oct 28INCY lead: Stable — the AIQ differential has held near 6 points over 30 sessions.
- Today
- INCY +6
- 62 vs 68
- 7 sessions ago
- Level
- 67 vs 67
- 30 sessions ago
- INCY +5
- 55 vs 60
- 90 sessions ago
- INCY +15
- 59 vs 74
The lead changed hands 2 times in this window, most recently on Oct 28 when INCY moved ahead of GSK.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 2 bearish / 1 neutral, conflicted
Only GSK
- Bollinger Band Squeeze — neutral, volatility, short horizon
- Death Cross Active — bearish, trend, long horizon (5.63%)
- Downtrend Structure Active — bearish, trend, long horizon
2 bullish / 0 bearish
Only INCY
- Golden Cross Active — bullish, trend, long horizon (11.99%)
Both carry 1 more signal that do not separate them: MACD Bullish Crossover.
GSK is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is up while the AIQ Score moved down 6 points over the same session — price and model disagree (price +1.71%, AIQ -6 points).
Price and the AIQ Score both moved up over the latest session (price +3.07%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1GSK closes the Risk Resilience gap — currently 25 points behind, the largest single contributor to INCY's edge.
- 2GSK's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3INCY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
INCY leads on balance| Metric | GSK | INCY |
|---|---|---|
| Revenue growth (YoY) | 10.2% | 31.5% |
| EPS growth (YoY) | -74.4% | 92.1% |
| Gross margin | 73.3% | 92.6% |
| Operating margin | 24.1% | 31.6% |
| Return on equity (TTM) | 28.3% | 29.7% |
| Debt to equity | 1.03 | 0.01 |
Performance
INCY leads 5 of 6 windows| Metric | GSK | INCY |
|---|---|---|
| 1 week (5 sessions) | -2.6% | 3% |
| 1 month (20 sessions) | 1.2% | -3.7% |
| 3 months (63 sessions) | -6.4% | -5% |
| 6 months (126 sessions) | -5.2% | 17.9% |
| Year to date | -0.6% | 18.3% |
| 1 year (252 sessions) | 12.7% | 28.1% |
Technicals
INCY has the stronger structure| Metric | GSK | INCY |
|---|---|---|
| RSI (14) | 60.4 | 57.8 |
| ADX (14) | 22.1 | 20.9 |
| Price vs 50-day | -0.1% | -0.4% |
| Price vs 200-day | -6.9% | 8.3% |
| Volatility (1M, annualized) | 28.5% | 31.4% |
Risk
INCY is the more resilient| Metric | GSK | INCY |
|---|---|---|
| Beta | 0.22 | 0.38 |
| Sharpe ratio | 0.4 | 0.77 |
| Sortino ratio | 0.7 | 1.34 |
| Max drawdown | -24.4% | -18.3% |
| Current drawdown | -20.3% | -10.1% |
| Annualized volatility | 26.5% | 33.7% |
| Value at risk (95%) | -2.4% | -2.7% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, GSK or INCY?
On the Algovestiq AIQ Score, INCY is the stronger of the two as of Oct 31, 2026, scoring 68 against GSK's 62. The edge comes from risk resilience and quality. GSK is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is GSK or INCY the better buy right now?
INCY carries the stronger systematic profile as of Oct 31, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor INCY over GSK?
The composite weights Quality, Value, Momentum and Risk Resilience. INCY leads Risk Resilience by 25 points; INCY leads Quality by 17 points; GSK leads Value by 15 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, GSK or INCY?
Analyst price targets imply +21.2% upside for GSK and +4.5% for INCY, so the Street currently favors GSK. That points the opposite way to the AIQ Score, which favors INCY. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, GSK or INCY?
GSK is the better-valued of the two on the peer-relative Value factor. GSK on the peer-relative Value factor, by 15 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, GSK or INCY?
INCY on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, GSK or INCY?
INCY on the Momentum factor, by 6 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, GSK or INCY?
INCY is the more resilient of the two, so the other name carries the higher downside risk. INCY on Risk Resilience, by 25 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is GSK more profitable than INCY?
INCY leads on the comparable margin measures — gross margin 73.3% vs 92.6%; operating margin 24.1% vs 31.6%; ttm roe 28.3% vs 29.7%.
Is INCY's lead over GSK getting stronger or weaker?
INCY lead: Stable — the AIQ differential has held near 6 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-29 and 2026-10-28. The lead has changed hands 2 times in that window, most recently on 2026-10-28, when INCY moved ahead of GSK.
What would change the GSK vs INCY verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: GSK closes the Risk Resilience gap — currently 25 points behind, the largest single contributor to INCY's edge; GSK's Death Cross Active resolves — a bearish trend rule currently active against it; INCY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about GSK and INCY?
GSK: 1 bullish / 2 bearish / 1 neutral, conflicted. INCY: 2 bullish / 0 bearish. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on GSK is Death Cross Active (bearish, long horizon). On INCY it is Golden Cross Active (bullish, long horizon).
Compare GSK and INCY with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.